Five Peptides Named: BPC-157, TB-500, GHK-Cu, CJC-1295 and Retatrutide Now a TGA Compliance Priority
The five names on the TGA's list
The TGA states that BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295 are examples of unapproved peptide products. None of these five is included in the Australian Register of Therapeutic Goods.
That register is the TGA's master list of medicines and devices assessed as meeting Australian standards. Being left off it is a specific regulatory fact, not a minor technicality.
The TGA states that because these products are not on the register, they have not been evaluated for safety, quality or effectiveness. That is three separate evaluation gaps, not one.
Why compliance priority status matters
The TGA states that unapproved peptide products have now been added as a priority focus area for compliance activity. This is a formal enforcement designation, not just public advice.
The focus covers three specific activities: unlawful importation, unlawful supply and unlawful advertising. Each is treated as a distinct compliance target under this priority.
Naming BPC-157, TB-500, GHK-Cu, CJC-1295 and retatrutide as examples signals which products compliance officers are most likely to scrutinise first. Where a peptide is named like this, it is worth noting that most peptides are prescription-only medicines in Australia.
What the Personal Importation Scheme actually requires
Australians can in some circumstances bring medicines in through the Personal Importation Scheme. But the TGA states that consumers using this scheme must hold a prescription or medical authorisation wherever one is required for that product.
This condition applies regardless of how a product is marketed or packaged overseas. A product being sold freely in another country does not remove the Australian authorisation requirement.
For substances like CJC-1295 or TB-500, where no evaluated authorisation pathway exists through the Register, this requirement becomes a significant practical barrier rather than a formality.
Where the TGA says consumers should look instead
The TGA advises Australians against unapproved peptide products, specifically naming those obtained online or from overseas as higher concern. This is a sourcing-based distinction, not a blanket statement about every peptide.
The TGA states that Australians should use only products supplied through Australian pharmacies. This narrows the recommended pathway to a single, identifiable channel.
This pharmacy-only guidance sits alongside the five named examples, BPC-157, GHK-Cu, TB-500, CJC-1295 and retatrutide, as the TGA's current public position on where risk is concentrated. It does not state that any of these five has since been approved.
Most peptides are prescription-only medicines in Australia. This article reports published research and regulation for general education and is not medical advice. Speak to your doctor.